Screener / SEC EDGAR /CIK 0000874015 /10-K filed Feb 26, 2026, compared with Feb 19, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Ionis Pharmaceuticals Inc IONS

Compare with peers Embed
Earnings releases

Latest results release: Nov 9, 2026

8-K item 2.02, exhibit 99

What IONS's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

What the company says its adjusted numbers leave out:

8 Reconciliation of GAAP to Non-GAAP Basis As illustrated in the Selected Financial Information in this press release, non-GAAP operating expenses, non- GAAP income (loss) from operations, and non-GAAP net income (loss) were adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effects. release Jul 29, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 9, 2026 · EX-99

Ionis reports third quarter 2026 financial results and highlights progress on

Open on SEC

Ionis reports third quarter 2026 financial results and highlights progress on key programs

– TRYNGOLZA ® (olezarsen) 2026 product sales guidance lowered as sHTG launch ramps more gradually than expected reflecting early dynamics of establishing a new treatment paradigm –

– DAWNZERA ® (donidalorsen) launch momentum continues; reaffirming 2026 product revenue guidance –

– Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2026.

“In 2026, we continue to advance innovative medicines for people with serious diseases, underscored by three approvals for groundbreaking first-in-class medicines, two of which are Ionis-owned,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “TRYNGOLZA, our first launch in a large indication, represents a new treatment paradigm for the underserved sHTG population. While initial sales progress has been more gradual than anticipated, we are encouraged by the underlying launch fundamentals. Importantly, we have identified clear opportunities to improve performance, and we remain confident in TRYNGOLZA's long-term growth potential. ZANVASTRO for people with Alexander disease marks our first independent neurology launch and lays the foundation for future launches from our leading neurology pipeline. In addition, our partnered pipeline continues to advance, with the recent approval of HIBSAGO for chronic hepatitis B and two additional positive Phase 3 outcomes creating near-term opportunities for additional potential approvals and revenue growth.”

Rec onc ili ati on of GAA P to non -GA AP bas is con tai ned lat er in thi s r ele ase . 1

Rev enu e in the thi rd qua rte r and nin e m ont hs end ed Sep tem ber 30, 202 6 i ncr eas ed by 55% and 64% res pec tiv ely , c omp are d to the sam e p eri ods las t y ear , e xcl udi ng the one -ti me sap abl urs en upf ron t p aym ent rec ogn ize d in the sec ond qua rte r of 202 5, dri ven by inc rea sed com mer cia l r eve nue and sub sta nti al R&D rev enu e f rom mul tip le par tne rsh ips

Ope rat ing exp ens es for the thi rd qua rte r and nin e m ont hs end ed Sep tem ber 30, 202 6 w ere in lin e w ith exp ect ati ons and inc rea sed yea r o ver yea r p rim ari ly fro m i nve stm ent s r ela ted to the com mer cia liz ati on eff ort s for TRY NGO LZA , D AWN ZER A and ZAN VAS TRO

End ed the thi rd qua rte r of 202 6 w ith cas h and sho rt- ter m i nve stm ent s of $1. 9 b ill ion

“In the third quarter, we generated higher quarter-over-quarter commercial revenue and substantial R&D revenue from partnered medicines while continuing to invest in our innovative wholly owned pipeline. Our commercial revenue growth was driven by DAWNZERA, which continues to gain momentum, supporting our confidence in achieving full-year DAWNZERA product sales guidance. These results keep us on track to achieve our 2026 total revenue, operating loss and cash guidance,” said Elizabeth L. Hougen, chief financial officer of Ionis. “We are lowering our 2026 TRYNGOLZA product sales guidance to reflect a more gradual ramp than we anticipated. We remain confident in TRYNGOLZA’s potential to deliver sustained, long-term revenue growth and multi-billion-dollar peak sales. As we execute on our independent launches and advance the many additional opportunities across our rich pipeline, we remain committed to achieving our goal of sustained positive cash flow and long-term value creation.”

TRY NGO LZA ® ( ole zar sen ), the fir st FDA -ap pro ved tre atm ent to red uce tri gly cer ide s and acu te pan cre ati tis ris k in adu lts wit h s eve re hyp ert rig lyc eri dem ia (sH TG) as an adj unc t to die t

Gen era ted U.S . net pro duc t s ale s of $9 mil lio n and $41 mil lio n in the thi rd qua rte r and nin e m ont hs end ed Sep tem ber 30, 202 6, res pec tiv ely ■

Ful l y ear 202 6 p rod uct sal es gui dan ce low ere d to app rox ima tel y $50 mil lio n, ref lec tin g a mor e g rad ual lau nch ram p t han ant ici pat ed as Ion is est abl ish es a new tre atm ent par adi gm for peo ple wit h s HTG o

FCS lau nch out sid e the U.S . u nde rwa y; rec eiv ed a p osi tiv e o pin ion fro m the Com mit tee for Med ici nal Pro duc ts for Hum an Use (CH MP) for sHT G ( sHT G f ast ing tri gly cer ide lev els of ≥88 0 m g/d L [ ≥10 mmo l/L ]), pav ing the way to bri ng TRY NGO LZA to sHT G p ati ent s a cro ss Eur ope wit h a fin al app rov al dec isi on exp ect ed in the fou rth qua rte r of 202 6

Pre sen ted pos iti ve res ult s f rom the COR E and COR E2 ope n-l abe l e xte nsi on stu dy (CO RE- OLE ) at the Eur ope an Soc iet y of Car dio log y ( ESC ) C ong res s in Aug ust 202 6

DAW NZE RA ® ( don ida lor sen ), the fir st and onl y R NA- tar get ed pro phy lac tic the rap y for her edi tar y a ngi oed ema (HA E) in pat ien ts 12 yea rs of age and old er

Gen era ted U.S . net pro duc t s ale s of $37 mil lio n and $79 mil lio n in the thi rd qua rte r and nin e m ont hs end ed Sep tem ber 30, 202 6, res pec tiv ely

On tra ck to ach iev e f ull yea r 2 026 pro duc t s ale s g uid anc e of $11 0- 120 mil lio n, rep res ent ing a c ont inu ing dri ver of yea r-o ver -ye ar rev enu e g row th 2 o

Lau nch out sid e the U.S . u nde rwa y, wit h new mar ket app rov als in Eur ope and Can ada

ZAN VAS TRO TM (zi lga ner sen ), the fir st and onl y d ise ase -mo dif yin g t rea tme nt app rov ed for chi ldr en and adu lts wit h A lex and er dis eas e ( AxD )

Com mer cia liz ing out sid e the U.S . w ith Rec ord ati , a ssu min g a ppr ova l

Obu dan ers en, a p ote nti al fir st- in- cla ss tre atm ent for Ang elm an syn dro me (AS )

Com ple ted enr oll men t in the Pha se 3 R EVE AL stu dy, wit h d ata exp ect ed in the sec ond hal f of 202 7

Ini tia ted Pha se 3 C HAM PIO N s tud y in peo ple wit h AS due to pat ern al uni par ent al dis omy (UP D), or imp rin tin g c ent er def ect s ( abb rev iat ed as eit her ID or ICD )

ION 775 , an inv est iga tio nal siR NA for sHT G w ith the pot ent ial for sem ian nua l or les s f req uen t d osi ng, ent ere d a Pha se 2 s tud y in peo ple wit h s HTG and mod era tel y e lev ate d t rig lyc eri des (HT G), bas ed on Pha se 1 r esu lts sho win g r obu st tri gly cer ide low eri ng wit h p ote nti al for ext end ed dos ing int erv als

Pre sen ted and pub lis hed pos iti ve res ult s f rom the Pha se 1 s tud y at ESC and in the Jou rna l of Cli nic al Lip ido log y in Aug ust 202 6

SPI NRA ZA ® ( nus ine rse n) for the tre atm ent of spi nal mus cul ar atr oph y ( SMA ) g ene rat ed glo bal sal es of $46 1 m ill ion in the thi rd qua rte r of 202 6, an inc rea se of 23% com par ed to the sam e p eri od in 202 5, res ult ing in roy alt y r eve nue of $69 mil lio n

WAI NUA ® ( epl ont ers en) (WA INZ UA in EU) for the tre atm ent of adu lts wit h p oly neu rop ath y of her edi tar y t ran sth yre tin -me dia ted amy loi dos is (AT TRv - PN) gen era ted glo bal sal es of $68 mil lio n in the thi rd qua rte r of 202 6, res ult ing in roy alt y r eve nue of $7 mil lio n

Glo bal WAI NUA ATT Rv- PN lau nch es con tin uin g w ith add iti ona l s ubm iss ion s in pro gre ss to fur the r e xpa nd glo bal WAI NUA acc ess o

Pre sen ted and pub lis hed Pha se 3 C ARD IO- TTR ans for m s tud y r esu lts of epl ont ers en for the tre atm ent of tra nst hyr eti n-m edi ate d a myl oid car dio myo pat hy (AT TR- CM) at ESC and in the New Eng lan d J our nal of Med ici ne in Aug ust 202 6. Alt hou gh the stu dy mis sed the pri mar y c omp osi te end poi nt in the ove ral l p opu lat ion , e plo nte rse n d emo nst rat ed nom ina l s ign ifi can ce in the pre -sp eci fie d m ono the rap y p opu lat ion and a f avo rab le saf ety and tol era bil ity pro fil e ●

HIB SAG O TM (be pir ovi rse n), fir st- in- cla ss tre atm ent for chr oni c h epa tit is B ( CHB )

Und er reg ula tor y r evi ew in add iti ona l c oun tri es, inc lud ing the EU and Chi na ●

Sef axe rse n, fir st RNA -ta rge ted pot ent ial tre atm ent for Imm uno glo bul in A N eph rop ath y ( IgA N) Presented positive results from the Phase 3 IMAgINATION study at ASN in October 2026. The study met its primary endpoint, demonstrating a clinically meaningful 43.1% reduction in proteinuria relative to placebo at week 37 (p<0.0001), with a safety profile consistent with previous data. Results will be shared with health authorities 3 ●

Ule fne rse n P has e 3 stu dy in pat ien ts wit h F use d in Sar com a ( FUS ) A myo tro phi c L ate ral Scl ero sis (AL S) met its pri mar y e ndp oin t ( p=0 .00 05) and dem ons tra ted a f avo rab le saf ety and tol era bil ity pro fil e; dat a to be sha red wit h h eal th aut hor iti es

Sap abl urs en, a p ote nti al tre atm ent for pol ycy the mia ver a, rec eiv ed Orp han Dru g D esi gna tio ns in the U.S ., EU and Jap an

Revenue: Three Nine Commerc… months months revenue: ended ended Product September (amounts September sales, 30, in 30, net: 2026 millions) 2025 2026 2025 ────────────────────────────────────────────────────────────────────────────── TRYNGOL… sales, $ 9 $ 32 $ 41 $ 57 net DAWNZERA sales, 37 1 79 1 net ZANVAST… sales, 2 - 2 - net Total product 48 33 122 58 sales, net Royalty revenue: SPINRAZA 69 56 167 158 royalti… WAINUA 7 13 34 33 royalti… Other 5 7 14 19 royalti… Total royalty 81 76 215 210 revenue Other commerc… 7 7 26 26 revenue Total commerc… 136 116 363 294 revenue Research and develop… revenue: Collabo… agreeme… 103 31 356 414 revenue WAINUA joint 4 10 38 32 develop… revenue Total research and 107 41 394 446 develop… revenue Total $ 243 $ 157 $ 757 $ 740 revenue

Commercial revenue for the third quarter and nine months ended September 30, 2026 increased 18% and 23%, respectively, compared to the same periods in 2025. This increase was primarily driven by DAWNZERA product sales. Research and development revenue was also higher in the third quarter and nine months ended September 30, 2026, compared to the same periods in 2025, driven by multiple payments for programs advancing under the Company’s R&D collaborations, and excluding the $280 million upfront payment for the global license of sapablursen to Ono Pharmaceutical Co., Ltd. the Company received in the second quarter of 2025.

Operating expenses for the third quarter and nine months ended September 30, 2026 increased year over year, in line with expectations, primarily from investments related to the commercialization efforts for TRYNGOLZA, DAWNZERA and ZANVASTRO, with full-year expenses remaining on track for low-teens percentage growth year-over-year. 4

As of September 30, 2026, Ionis’ cash, cash equivalents and short-term investments decreased to $1.9 billion, compared to $2.7 billion on December 31, 2025, primarily due to repayment of the 0% convertible notes on April 1, 2026 and cash used to fund operations.

Ionis reaffirms its 2026 total revenue, including DAWNZERA product sales, operating loss and cash guidance based on its year-to-date results and fourth quarter outlook. Following the first full quarter of the TRYNGOLZA launch as the first and only treatment to reduce triglycerides and acute pancreatitis in people living with severe hypertriglyceridemia, Ionis is lowering TRYNGOLZA 2026 product sales guidance to reflect a more gradual-than-anticipated near-term launch ramp, while remaining confident in TRYNGOLZA’s long-term growth potential.

Full Year 2026 Guidance Previous Guidance New Guidance Total Revenue $875-900 million Unchanged TRYNGOLZA product sales, net $100-110 million ~$50 million DAWNZERA product sales, net $110-120 million Unchanged Operating loss on a non-GAAP basis $425-475 million Unchanged Cash, cash equivalents and short-term >$1.6 billion Unchanged investments

Management will host a conference call and webcast to discuss Ionis’ third quarter 2026 results at 9:00 a.m. Eastern time on Monday, November 9, 2026. Interested parties may access the webcast here . A webcast replay will be available for a limited time at the same address. To access the Company’s third quarter 2026 earnings slides click here .

(olezarsen): TRYNGOLZA was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides (TG) and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG ≥500 mg/dL) and as an adjunct to diet to reduce TG in adults with familial chylomicronemia syndrome (FCS). For more information about TRYNGOLZA, including the full U.S. Prescribing Information, visit

(donidalorsen): DAWNZERA was approved by the U.S. Food and Drug Administration for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. For more information about DAWNZERA, including the full U.S. Prescribing Information, visit

(zilganersen): ZANVASTRO was approved by the U.S. Food and Drug Administration for the treatment of Alexander disease (AxD) in pediatric and adult patients. For more information about ZANVASTRO, including the full U.S. Prescribing Information, visit

5 For more information about SPINRAZA, WAINUA, HIBSAGO and QALSODY, visit spinraza.com , wainua.com , hibsago.com , qalsody.com , respectively. QALSODY is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval may be contingent upon verification of clinical benefit in confirmatory trial(s).

For more than three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life- changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram .

This press release includes forward-looking statements regarding Ionis’ business, financial guidance and the therapeutic and commercial potential of our commercial medicines, additional medicines in development, technologies and our expectations regarding development and regulatory milestones. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward- looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2025, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our” and “us” all refer to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals ® is a registered trademark of Ionis Pharmaceuticals, Inc. TRYNGOLZA ® is a registered trademark of Ionis Pharmaceuticals, Inc. DAWNZERA ® is a registered trademark of Ionis Pharmaceuticals, Inc. ZANVASTRO TM is a trademark of Ionis Pharmaceuticals, Inc. AKCEA TM is a trademark of Akcea Therapeutics, Inc. TEGSEDI TM is a trademark of Akcea Therapeutics, Inc. WAYLIVRA TM is a trademark of Akcea Therapeutics, Inc. SPINRAZA ® and QALSODY ® are registered trademarks of Biogen. WAINUA ® is a registered trademark of the AstraZeneca group of companies. HIBSAGO TM is a trademark of the GSK group of companies. Ionis Investor Contact:

As illustrated in the Selected Financial Information in this press release, non- GAAP operating expenses, non-GAAP loss from operations, and non-GAAP net loss were adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effects. Compensation expense related to equity awards are non-cash. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Ionis reports these non-GAAP results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Ionis’ non-GAAP results is consistent with how Ionis’ management internally evaluates the performance of its operations. 9

September 30, December 31, Assets: 2026 (unaudited) 2025 ────────────────────────────────────────────────────────────────────────────── Cash, cash equivalents and short-term $ 1,884 $ 2,677 investments Contracts receivable 88 66 Other current assets 389 247 Property, plant and 162 123 equipment, net Right-of-use assets 228 239 Other assets 162 172 Total assets $ 2,913 $ 3,524 Liabilities and stockholders’ equity: Current portion of deferred contract $ 70 $ 74 revenue 0% convertible senior notes due April - 432 2026, net – current Liability related to sale of future 138 12 royalties, net – current Other current 227 265 liabilities 0% convertible senior notes due 2030, 754 751 net 1.75% convertible senior notes due 2028, 570 568 net Liability related to sale of future 428 551 royalties, net Long-term lease 262 262 liabilities Long-term obligations, less current 21 28 portion Long-term deferred 49 92 contract revenue Total stockholders’ 394 489 equity Total liabilities and stockholders’ $ 2,913 $ 3,524 equity

New Product Launches Program Indication Location 2026 2027 DAWNZERA HAE EU Achieved TRYNGOLZA sHTG U.S. Achieved EU • ZANVASTRO Alexander disease U.S. Achieved HIBSAGO CHB Japan Achieved U.S. • EU • China • Sefaxersen IgAN U.S. • Ulefnersen FUS-ALS U.S. •

Regulatory Actions Program Indication Regulatory Action 2026 2027 Donidalorsen HAE EU approval Achieved decision Olezarsen sHTG U.S. approval Achieved decision EU submission Achieved EU approval • decision Zilganersen Alexander disease U.S. submission Achieved U.S. approval Achieved decision Nusinersen SMA EU approval Achieved (high dose) decision U.S. approval Achieved decision Bepirovirsen CHB Regulatory Achieved submission(s) U.S. and Japan approval Achieved decisions EU approval • decision China approval • decision Pelacarsen Lp(a)- CVD U.S. submission Not Achieved Sefaxersen IgAN U.S. submission • U.S. approval • Ulefnersen FUS-ALS U.S. submission • U.S. approval •

Key Phase 3 Clinical Events Program Indication Event 2026 2027 Obudanersen Angelman syndrome REVEAL fully Achieved enrolled REVEAL data • Bepirovirsen CHB B-Well data Achieved Pelacarsen Lp(a)-CVD Lp(a) HORIZON data Not Achieved Eplontersen ATTR-CM CARDIO-TTRansform Not Achieved data Sefaxersen IgAN IMAgINATION Achieved interim data IMAgINATION data • Ulefnersen FUS-ALS FUSION data Achieved Salanersen SMA Phase 3 initiation Achieved Sapablursen Polycythemia Vera Phase 3 initiation Achieved Diranersen Alzheimer’s Phase 3 initiation • disease

Tim ing exp ect ati ons bas ed on cur ren t a ssu mpt ion s and sub jec t to cha nge . ●

Ind ica tes tha t the mil est one is ant ici pat ed in the yea r i ndi cat ed. # # #

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
 Ionis reports third quarter 2026 financial results and highlights progress on  
                                  key programs                                  
                                                                                
  – ZANVASTRO TM (zilganersen) first approved medicine for Alexander disease;   
      first independent launch underway from leading neurology pipeline –       
                                                                                
  – TRYNGOLZA ® (olezarsen) 2026 product sales guidance lowered as sHTG launch  
 ramps more gradually than expected reflecting early dynamics of establishing a 
                            new treatment paradigm –                            
                                                                                
– DAWNZERA ® (donidalorsen) launch momentum continues; reaffirming 2026 product 
                               revenue guidance –                               
                                                                                
      – Reaffirming 2026 total revenue, operating loss and cash guidance –      
                                                                                
  CARLSBAD, Calif., November 9, 2026                                            
                                                                                
– Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported
financial results and provided key updates for the third quarter ended September
30, 2026.

“In 2026, we continue to advance innovative medicines for people with serious
diseases, underscored by three approvals for groundbreaking first-in-class
medicines, two of which are Ionis-owned,” said Brett P. Monia, Ph.D., chief
executive officer of Ionis. “TRYNGOLZA, our first launch in a large indication,
represents a new treatment paradigm for the underserved sHTG population. While
initial sales progress has been more gradual than anticipated, we are encouraged
by the underlying launch fundamentals. Importantly, we have identified clear
opportunities to improve performance, and we remain confident in TRYNGOLZA's
long-term growth potential. ZANVASTRO for people with Alexander disease marks
our first independent neurology launch and lays the foundation for future
launches from our leading neurology pipeline. In addition, our partnered
pipeline continues to advance, with the recent approval of HIBSAGO for chronic
hepatitis B and two additional positive Phase 3 outcomes creating near-term
opportunities for additional potential approvals and revenue growth.”
                                                                                
  Third Quarter 2026 Summary Financial Results                                  
                                                                                
(
                                                                                
  1)                                                                            
                                                                                
:
                                                                                
          Three                                                                 
          mont…                                                                 
          ended                                                                 
          Sept…                              Nine                               
          30,                                months                             
          2026                               ended                              
          (amo…                              Septe…                             
          in                                 30,                                
          mill…             2025             2026                2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Tot…    $       243       $      157       $         757       $      740     
  rev…                                                                          
  Ope…    $       373       $      317       $       1,107       $      907     
  exp…                                                                          
  Ope…                                                                          
  exp…                                                                          
  on a    $       330       $      286       $         975       $      816     
  non…                                                                          
  bas…                                                                          
  Loss                                                                          
  from    $      (130  )    $     (160  )    $        (350  )    $     (167  )  
  ope…                                                                          
  Loss                                                                          
  from                                                                          
  ope…    $       (87  )    $     (129  )    $        (218  )    $      (76  )  
  on a                                                                          
  non…                                                                          
  bas…                                                                          
                                                                                
(1)

Rec
onc
ili
ati
on
of
GAA
P
to
non
-GA
AP
bas
is
con
tai
ned
lat
er
in
thi
s r
ele
ase
.
                                       1                                        
                                                                                
  Third Quarter 2026 Financial Highlights                                       
                                                                                
●

Rev
enu
e
in
the
thi
rd
qua
rte
r
and
nin
e m
ont
hs
end
ed
Sep
tem
ber
30,
202
6 i
ncr
eas
ed
by
55%
and
64%
res
pec
tiv
ely
, c
omp
are
d
to
the
sam
e p
eri
ods
las
t y
ear
, e
xcl
udi
ng
the
one
-ti
me
sap
abl
urs
en
upf
ron
t p
aym
ent
rec
ogn
ize
d
in
the
sec
ond
qua
rte
r
of
202
5,
dri
ven
by
inc
rea
sed
com
mer
cia
l r
eve
nue
and
sub
sta
nti
al
R&D
rev
enu
e f
rom
mul
tip
le
par
tne
rsh
ips

●

Ope
rat
ing
exp
ens
es
for
the
thi
rd
qua
rte
r
and
nin
e m
ont
hs
end
ed
Sep
tem
ber
30,
202
6 w
ere
in
lin
e w
ith
exp
ect
ati
ons
and
inc
rea
sed
yea
r o
ver
yea
r p
rim
ari
ly
fro
m i
nve
stm
ent
s r
ela
ted
to
the
com
mer
cia
liz
ati
on
eff
ort
s
for
TRY
NGO
LZA
, D
AWN
ZER
A
and
ZAN
VAS
TRO

●

End
ed
the
thi
rd
qua
rte
r
of
202
6 w
ith
cas
h
and
sho
rt-
ter
m i
nve
stm
ent
s
of
$1.
9 b
ill
ion
                                                                                
  Third Quarter 2026 Financial Results                                          
                                                                                
“In the third quarter, we generated higher quarter-over-quarter commercial
revenue and substantial R&D revenue from partnered medicines while continuing to
invest in our innovative wholly owned pipeline. Our commercial revenue growth
was driven by DAWNZERA, which continues to gain momentum, supporting our
confidence in achieving full-year DAWNZERA product sales guidance. These results
keep us on track to achieve our 2026 total revenue, operating loss and cash
guidance,” said Elizabeth L. Hougen, chief financial officer of Ionis. “We are
lowering our 2026 TRYNGOLZA product sales guidance to reflect a more gradual
ramp than we anticipated. We remain confident in TRYNGOLZA’s potential to
deliver sustained, long-term revenue growth and multi-billion-dollar peak sales.
As we execute on our independent launches and advance the many additional
opportunities across our rich pipeline, we remain committed to achieving our
goal of sustained positive cash flow and long-term value creation.”
                                                                                
  Recent Highlights - Wholly Owned Medicines                                    
                                                                                
●

TRY
NGO
LZA
® (
ole
zar
sen
),
the
fir
st
FDA
-ap
pro
ved
tre
atm
ent
to
red
uce
tri
gly
cer
ide
s
and
acu
te
pan
cre
ati
tis
ris
k
in
adu
lts
wit
h s
eve
re
hyp
ert
rig
lyc
eri
dem
ia
(sH
TG)
as
an
adj
unc
t
to
die
t

o

Gen
era
ted
U.S
.
net
pro
duc
t s
ale
s
of
$9
mil
lio
n
and
$41
mil
lio
n
in
the
thi
rd
qua
rte
r
and
nin
e m
ont
hs
end
ed
Sep
tem
ber
30,
202
6,
res
pec
tiv
ely
■

Ful
l y
ear
202
6 p
rod
uct
sal
es
gui
dan
ce
low
ere
d
to
app
rox
ima
tel
y
$50
mil
lio
n,
ref
lec
tin
g a
mor
e g
rad
ual
lau
nch
ram
p t
han
ant
ici
pat
ed
as
Ion
is
est
abl
ish
es
a
new
tre
atm
ent
par
adi
gm
for
peo
ple
wit
h s
HTG
o

FCS
lau
nch
out
sid
e
the
U.S
. u
nde
rwa
y;
rec
eiv
ed
a p
osi
tiv
e o
pin
ion
fro
m
the
Com
mit
tee
for
Med
ici
nal
Pro
duc
ts
for
Hum
an
Use
(CH
MP)
for
sHT
G (
sHT
G f
ast
ing
tri
gly
cer
ide
lev
els
of
≥88
0 m
g/d
L [
≥10
mmo
l/L
]),
pav
ing
the
way
to
bri
ng
TRY
NGO
LZA
to
sHT
G p
ati
ent
s a
cro
ss
Eur
ope
wit
h a
fin
al
app
rov
al
dec
isi
on
exp
ect
ed
in
the
fou
rth
qua
rte
r
of
202
6

o

Pre
sen
ted
pos
iti
ve
res
ult
s f
rom
the
COR
E
and
COR
E2
ope
n-l
abe
l e
xte
nsi
on
stu
dy
(CO
RE-
OLE
)
at
the
Eur
ope
an
Soc
iet
y
of
Car
dio
log
y (
ESC
) C
ong
res
s
in
Aug
ust
202
6

●

DAW
NZE
RA
® (
don
ida
lor
sen
),
the
fir
st
and
onl
y R
NA-
tar
get
ed
pro
phy
lac
tic
the
rap
y
for
her
edi
tar
y a
ngi
oed
ema
(HA
E)
in
pat
ien
ts
12
yea
rs
of
age
and
old
er

o

Gen
era
ted
U.S
.
net
pro
duc
t s
ale
s
of
$37
mil
lio
n
and
$79
mil
lio
n
in
the
thi
rd
qua
rte
r
and
nin
e m
ont
hs
end
ed
Sep
tem
ber
30,
202
6,
res
pec
tiv
ely

o

On
tra
ck
to
ach
iev
e f
ull
yea
r 2
026
pro
duc
t s
ale
s g
uid
anc
e
of
$11
0-
120
mil
lio
n,
rep
res
ent
ing
a c
ont
inu
ing
dri
ver
of
yea
r-o
ver
-ye
ar
rev
enu
e g
row
th
                                       2                                        
o

Lau
nch
out
sid
e
the
U.S
. u
nde
rwa
y,
wit
h
new
mar
ket
app
rov
als
in
Eur
ope
and
Can
ada

●

ZAN
VAS
TRO
TM
(zi
lga
ner
sen
),
the
fir
st
and
onl
y d
ise
ase
-mo
dif
yin
g t
rea
tme
nt
app
rov
ed
for
chi
ldr
en
and
adu
lts
wit
h A
lex
and
er
dis
eas
e (
AxD
)

o

Lau
nch
und
erw
ay
wit
h f
irs
t p
ati
ent
s d
ose
d w
ith
com
mer
cia
l d
rug

o

Com
mer
cia
liz
ing
out
sid
e
the
U.S
. w
ith
Rec
ord
ati
, a
ssu
min
g a
ppr
ova
l

●

Obu
dan
ers
en,
a p
ote
nti
al
fir
st-
in-
cla
ss
tre
atm
ent
for
Ang
elm
an
syn
dro
me
(AS
)

o

Com
ple
ted
enr
oll
men
t
in
the
Pha
se
3 R
EVE
AL
stu
dy,
wit
h d
ata
exp
ect
ed
in
the
sec
ond
hal
f
of
202
7

o

Ini
tia
ted
Pha
se
3 C
HAM
PIO
N s
tud
y
in
peo
ple
wit
h
AS
due
to
pat
ern
al
uni
par
ent
al
dis
omy
(UP
D),
or
imp
rin
tin
g c
ent
er
def
ect
s (
abb
rev
iat
ed
as
eit
her
ID
or
ICD
)

●

ION
775
,
an
inv
est
iga
tio
nal
siR
NA
for
sHT
G w
ith
the
pot
ent
ial
for
sem
ian
nua
l
or
les
s f
req
uen
t d
osi
ng,
ent
ere
d a
Pha
se
2 s
tud
y
in
peo
ple
wit
h s
HTG
and
mod
era
tel
y e
lev
ate
d t
rig
lyc
eri
des
(HT
G),
bas
ed
on
Pha
se
1 r
esu
lts
sho
win
g r
obu
st
tri
gly
cer
ide
low
eri
ng
wit
h p
ote
nti
al
for
ext
end
ed
dos
ing
int
erv
als

o

Pre
sen
ted
and
pub
lis
hed
pos
iti
ve
res
ult
s f
rom
the
Pha
se
1 s
tud
y
at
ESC
and
in
the
Jou
rna
l
of
Cli
nic
al
Lip
ido
log
y
in
Aug
ust
202
6
                                                                                
  Recent Highlights – Partnered Medicines                                       
                                                                                
●

SPI
NRA
ZA
® (
nus
ine
rse
n)
for
the
tre
atm
ent
of
spi
nal
mus
cul
ar
atr
oph
y (
SMA
) g
ene
rat
ed
glo
bal
sal
es
of
$46
1 m
ill
ion
in
the
thi
rd
qua
rte
r
of
202
6,
an
inc
rea
se
of
23%
com
par
ed
to
the
sam
e p
eri
od
in
202
5,
res
ult
ing
in
roy
alt
y r
eve
nue
of
$69
mil
lio
n

●

WAI
NUA
® (
epl
ont
ers
en)
(WA
INZ
UA
in
EU)
for
the
tre
atm
ent
of
adu
lts
wit
h p
oly
neu
rop
ath
y
of
her
edi
tar
y t
ran
sth
yre
tin
-me
dia
ted
amy
loi
dos
is
(AT
TRv
-
PN)
gen
era
ted
glo
bal
sal
es
of
$68
mil
lio
n
in
the
thi
rd
qua
rte
r
of
202
6,
res
ult
ing
in
roy
alt
y r
eve
nue
of
$7
mil
lio
n

o

Glo
bal
WAI
NUA
ATT
Rv-
PN
lau
nch
es
con
tin
uin
g w
ith
add
iti
ona
l s
ubm
iss
ion
s
in
pro
gre
ss
to
fur
the
r e
xpa
nd
glo
bal
WAI
NUA
acc
ess
o

Pre
sen
ted
and
pub
lis
hed
Pha
se
3 C
ARD
IO-
TTR
ans
for
m s
tud
y r
esu
lts
of
epl
ont
ers
en
for
the
tre
atm
ent
of
tra
nst
hyr
eti
n-m
edi
ate
d a
myl
oid
car
dio
myo
pat
hy
(AT
TR-
CM)
at
ESC
and
in
the
New
Eng
lan
d J
our
nal
of
Med
ici
ne
in
Aug
ust
202
6.
Alt
hou
gh
the
stu
dy
mis
sed
the
pri
mar
y c
omp
osi
te
end
poi
nt
in
the
ove
ral
l p
opu
lat
ion
, e
plo
nte
rse
n d
emo
nst
rat
ed
nom
ina
l s
ign
ifi
can
ce
in
the
pre
-sp
eci
fie
d m
ono
the
rap
y p
opu
lat
ion
and
a f
avo
rab
le
saf
ety
and
tol
era
bil
ity
pro
fil
e
●

HIB
SAG
O
TM
(be
pir
ovi
rse
n),
fir
st-
in-
cla
ss
tre
atm
ent
for
chr
oni
c h
epa
tit
is
B (
CHB
)

o

App
rov
ed
in
the
U.S
.,
Jap
an
and
Can
ada

o

Und
er
reg
ula
tor
y r
evi
ew
in
add
iti
ona
l c
oun
tri
es,
inc
lud
ing
the
EU
and
Chi
na
●

Sef
axe
rse
n,
fir
st
RNA
-ta
rge
ted
pot
ent
ial
tre
atm
ent
for
Imm
uno
glo
bul
in
A N
eph
rop
ath
y (
IgA
N)
Presented positive results from the Phase 3 IMAgINATION study at ASN in October
2026. The study met its primary endpoint, demonstrating a clinically meaningful
43.1% reduction in proteinuria relative to placebo at week 37 (p<0.0001), with a
safety profile consistent with previous data. Results will be shared with health
authorities
                                       3                                        
●

Ule
fne
rse
n P
has
e 3
stu
dy
in
pat
ien
ts
wit
h F
use
d
in
Sar
com
a (
FUS
) A
myo
tro
phi
c L
ate
ral
Scl
ero
sis
(AL
S)
met
its
pri
mar
y e
ndp
oin
t (
p=0
.00
05)
and
dem
ons
tra
ted
a f
avo
rab
le
saf
ety
and
tol
era
bil
ity
pro
fil
e;
dat
a
to
be
sha
red
wit
h h
eal
th
aut
hor
iti
es

●

Sap
abl
urs
en,
a p
ote
nti
al
tre
atm
ent
for
pol
ycy
the
mia
ver
a,
rec
eiv
ed
Orp
han
Dru
g D
esi
gna
tio
ns
in
the
U.S
.,
EU
and
Jap
an
                                                                                
  Revenue                                                                       
                                                                                
Ionis’ revenue was comprised of the following:
                                                                                
  Revenue:    Three                                Nine                         
  Commerc…    months                               months                       
  revenue:    ended                                ended                        
  Product     September   (amounts                 September                    
  sales,      30,               in                 30,                          
  net:        2026       millions)    2025         2026              2025       
 ────────────────────────────────────────────────────────────────────────────── 
  TRYNGOL…                                                                      
  sales,      $                  9    $      32    $           41    $      57  
  net                                                                           
  DAWNZERA                                                                      
  sales,                        37            1                79            1  
  net                                                                           
  ZANVAST…                                                                      
  sales,                         2            -                 2            -  
  net                                                                           
  Total                                                                         
  product                       48           33               122           58  
  sales,                                                                        
  net                                                                           
  Royalty                                                                       
  revenue:                                                                      
  SPINRAZA                      69           56               167          158  
  royalti…                                                                      
  WAINUA                         7           13                34           33  
  royalti…                                                                      
  Other                          5            7                14           19  
  royalti…                                                                      
  Total                                                                         
  royalty                       81           76               215          210  
  revenue                                                                       
  Other                                                                         
  commerc…                       7            7                26           26  
  revenue                                                                       
  Total                                                                         
  commerc…                     136          116               363          294  
  revenue                                                                       
  Research                                                                      
  and                                                                           
  develop…                                                                      
  revenue:                                                                      
  Collabo…                                                                      
  agreeme…                     103           31               356          414  
  revenue                                                                       
  WAINUA                                                                        
  joint                          4           10                38           32  
  develop…                                                                      
  revenue                                                                       
  Total                                                                         
  research                                                                      
  and                          107           41               394          446  
  develop…                                                                      
  revenue                                                                       
  Total       $                243    $     157    $          757    $     740  
  revenue                                                                       
                                                                                
Commercial revenue for the third quarter and nine months ended September 30,
2026 increased 18% and 23%, respectively, compared to the same periods in 2025.
This increase was primarily driven by DAWNZERA product sales. Research and
development revenue was also higher in the third quarter and nine months ended
September 30, 2026, compared to the same periods in 2025, driven by multiple
payments for programs advancing under the Company’s R&D collaborations, and
excluding the $280 million upfront payment for the global license of sapablursen
to Ono Pharmaceutical Co., Ltd. the Company received in the second quarter of
2025.
                                                                                
  Operating Expenses                                                            
                                                                                
Operating expenses for the third quarter and nine months ended September 30,
2026 increased year over year, in line with expectations, primarily from
investments related to the commercialization efforts for TRYNGOLZA, DAWNZERA and
ZANVASTRO, with full-year expenses remaining on track for low-teens percentage
growth year-over-year.
                                       4                                        
                                                                                
  Balance Sheet                                                                 
                                                                                
As of September 30, 2026, Ionis’ cash, cash equivalents and short-term
investments decreased to $1.9 billion, compared to $2.7 billion on December 31,
2025, primarily due to repayment of the 0% convertible notes on April 1, 2026
and cash used to fund operations.
                                                                                
  2026 Financial Guidance                                                       
                                                                                
Ionis reaffirms its 2026 total revenue, including DAWNZERA product sales,
operating loss and cash guidance based on its year-to-date results and fourth
quarter outlook. Following the first full quarter of the TRYNGOLZA launch as the
first and only treatment to reduce triglycerides and acute pancreatitis in
people living with severe hypertriglyceridemia, Ionis is lowering TRYNGOLZA 2026
product sales guidance to reflect a more gradual-than-anticipated near-term
launch ramp, while remaining confident in TRYNGOLZA’s long-term growth
potential.
                                                                                
  Full Year 2026 Guidance                      Previous Guidance  New Guidance  
  Total Revenue                                $875-900 million   Unchanged     
  TRYNGOLZA product sales, net                 $100-110 million   ~$50 million  
  DAWNZERA product sales, net                  $110-120 million   Unchanged     
  Operating loss on a non-GAAP basis           $425-475 million   Unchanged     
  Cash, cash equivalents and short-term        >$1.6 billion      Unchanged     
  investments                                                                   
                                                                                
                                                                                
  Webcast and Other Updates                                                     
                                                                                
Management will host a conference call and webcast to discuss Ionis’ third
quarter 2026 results at 9:00 a.m. Eastern time on Monday, November 9, 2026.
Interested parties may access the webcast here . A webcast replay will be
available for a limited time at the same address. To access the Company’s third
quarter 2026 earnings slides click here .
                                                                                
  Ionis’ Marketed Medicines                                                     
                                                                                
                                                                                
  TRYNGOLZA                                                                     
                                                                                
                                                                                
  ®                                                                             
                                                                                
(olezarsen): TRYNGOLZA was approved by the U.S. Food and Drug Administration as
an adjunct to diet to reduce triglycerides (TG) and the risk of acute
pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG ≥500 mg/dL)
and as an adjunct to diet to reduce TG in adults with familial chylomicronemia
syndrome (FCS). For more information about TRYNGOLZA, including the full U.S.
Prescribing Information, visit
                                                                                
  tryngolza.com                                                                 
                                                                                
                                                                                
  .                                                                             
                                                                                
                                                                                
  DAWNZERA                                                                      
                                                                                
                                                                                
  ®                                                                             
                                                                                
(donidalorsen): DAWNZERA was approved by the U.S. Food and Drug Administration
for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and
pediatric patients 12 years of age and older. For more information about
DAWNZERA, including the full U.S. Prescribing Information, visit
                                                                                
  dawnzera.com                                                                  
                                                                                
                                                                                
  .                                                                             
                                                                                
                                                                                
  ZANVASTRO                                                                     
                                                                                
                                                                                
  TM                                                                            
                                                                                
(zilganersen): ZANVASTRO was approved by the U.S. Food and Drug Administration
for the treatment of Alexander disease (AxD) in pediatric and adult patients.
For more information about ZANVASTRO, including the full U.S. Prescribing
Information, visit
                                                                                
  zanvastro.com                                                                 
                                                                                
                                                                                
  .                                                                             
                                                                                
                                       5                                        
For more information about SPINRAZA, WAINUA, HIBSAGO and QALSODY, visit
spinraza.com , wainua.com , hibsago.com , qalsody.com , respectively. QALSODY is
approved under accelerated approval based on reduction in plasma neurofilament
light chain (NfL) observed in patients treated with QALSODY. Continued approval
may be contingent upon verification of clinical benefit in confirmatory
trial(s).
                                                                                
  About Ionis Pharmaceuticals, Inc.                                             
                                                                                
For more than three decades, Ionis has invented medicines that bring better
futures to people with serious diseases. Ionis currently has marketed medicines
and a leading pipeline in neurology, cardiometabolic disease and select areas of
high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to
drive innovation in RNA therapies in addition to advancing new approaches in
gene editing. A deep understanding of disease biology and industry-leading
technology propels our work, coupled with a passion and urgency to deliver life-
changing advances for patients. To learn more about Ionis, visit Ionis.com and
follow us on X (Twitter) , LinkedIn and Instagram .
                                                                                
  Ionis Forward-looking Statements                                              
                                                                                
This press release includes forward-looking statements regarding Ionis’
business, financial guidance and the therapeutic and commercial potential of our
commercial medicines, additional medicines in development, technologies and our
expectations regarding development and regulatory milestones. Any statement
describing Ionis’ goals, expectations, financial or other projections,
intentions or beliefs is a forward-looking statement and should be considered an
at-risk statement. Such statements are subject to certain risks and
uncertainties including those inherent in the process of discovering, developing
and commercializing medicines that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around such medicines.
Ionis’ forward-looking statements also involve assumptions that, if they never
materialize or prove correct, could cause its results to differ materially from
those expressed or implied by such forward-looking statements. Although Ionis’
forward-looking statements reflect the good faith judgment of its management,
these statements are based only on facts and factors currently known by Ionis.
Except as required by law, we undertake no obligation to update any forward-
looking statements for any reason. As a result, you are cautioned not to rely on
these forward-looking statements. These and other risks concerning Ionis'
programs are described in additional detail in Ionis' annual report on Form 10-K
for the year ended December 31, 2025, and most recent Form 10-Q, which are on
file with the Securities and Exchange Commission. Copies of these and other
documents are available from the Company.

In this press release, unless the context requires otherwise, “Ionis,”
“Company,” “we,” “our” and “us” all refer to Ionis Pharmaceuticals and its
subsidiaries.

Ionis Pharmaceuticals ® is a registered trademark of Ionis Pharmaceuticals, Inc.
TRYNGOLZA ® is a registered trademark of Ionis Pharmaceuticals, Inc. DAWNZERA ®
is a registered trademark of Ionis Pharmaceuticals, Inc. ZANVASTRO TM is a
trademark of Ionis Pharmaceuticals, Inc. AKCEA TM is a trademark of Akcea
Therapeutics, Inc. TEGSEDI TM is a trademark of Akcea Therapeutics, Inc.
WAYLIVRA TM is a trademark of Akcea Therapeutics, Inc. SPINRAZA ® and QALSODY ®
are registered trademarks of Biogen. WAINUA ® is a registered trademark of the
AstraZeneca group of companies. HIBSAGO TM is a trademark of the GSK group of
companies.
Ionis Investor Contact:

D. Wade Walke, Ph.D.

[email protected]

760-603-2331

Ionis Media Contact:

Hayley Soffer

[email protected]

760-603-4679
                                       6                                        
                                                                                
                          IONIS PHARMACEUTICALS, INC.                           
                                                                                
                                                                                
                         SELECTED FINANCIAL INFORMATION                         
                                                                                
                                                                                
                Condensed Consolidated Statements of Operations                 
                                                                                
                      (In Millions, Except Per Share Data)                      
                                                                                
                 Three                               Nine                       
                months                             months                       
                 ended                              ended                       
               Septem…                            Septem…                       
  Reven…           30,                                30,                       
  Comme…          2026              2025             2026              2025     
  reven…       (unaud…          (unaudi…          (unaud…          (unaudi…     
 ────────────────────────────────────────────────────────────────────────────── 
  Produ…                                                                        
  sales,    $       48       $        33       $      122       $        58     
  net                                                                           
  Royal…            81                76              215               210     
  reven…                                                                        
  Other                                                                         
  comme…             7                 7               26                26     
  reven…                                                                        
  Total                                                                         
  comme…           136               116              363               294     
  reven…                                                                        
  Resea…                                                                        
  and                                                                           
  devel…                                                                        
  reven…                                                                        
  Colla…                                                                        
  agree…           103                31              356               414     
  reven…                                                                        
  WAINUA                                                                        
  joint              4                10               38                32     
  devel…                                                                        
  reven…                                                                        
  Total                                                                         
  resea…                                                                        
  and              107                41              394               446     
  devel…                                                                        
  reven…                                                                        
  Total            243               157              757               740     
  reven…                                                                        
  Expen…                                                                        
  Cost                                                                          
  of                 3                 2                9                 8     
  sales                                                                         
  Resea…                                                                        
  devel…           216               218              643               636     
  and                                                                           
  patent                                                                        
  Selli…                                                                        
  gener…           154                97              455               263     
  and                                                                           
  admin…                                                                        
  Total                                                                         
  opera…           373               317            1,107               907     
  expen…                                                                        
  Loss                                                                          
  from            (130  )           (160  )          (350  )           (167  )  
  opera…                                                                        
  Other                                                                         
  income                                                                        
  (expe…                                                                        
  Inter…                                                                        
  expen…                                                                        
  relat…                                                                        
  to the            (4  )            (18  )           (39  )            (55  )  
  sale                                                                          
  of                                                                            
  future                                                                        
  royal…                                                                        
  Other                                                                         
  incom…            24                49               73                70     
  net                                                                           
  Loss                                                                          
  before                                                                        
  income          (110  )           (129  )          (316  )           (152  )  
  tax                                                                           
  benef…                                                                        
  (expe…                                                                        
  Income                                                                        
  tax                -                 -               (1  )              -     
  benef…                                                                        
  (expe…                                                                        
  Net       $     (110  )    $      (129  )    $     (317  )    $      (152  )  
  loss                                                                          
  Basic                                                                         
  and                                                                           
  dilut…                                                                        
  net       $    (0.66  )    $     (0.80  )    $    (1.92  )    $     (0.95  )  
  loss                                                                          
  per                                                                           
  share                                                                         
  Shares                                                                        
  used                                                                          
  in                                                                            
  compu…                                                                        
  basic                                                                         
  and              166               160              166               159     
  dilut…                                                                        
  net                                                                           
  loss                                                                          
  per                                                                           
  share                                                                         
                                                                                
                                       7                                        
                                                                                
                          IONIS PHARMACEUTICALS, INC.                           
                                                                                
                   Reconciliation of GAAP to Non-GAAP Basis:                    
                                                                                
 Condensed Consolidated Operating Expenses, Loss From Operations, and Net Loss  
                                                                                
                                 (In Millions)                                  
                                                                                
          Three                                                                 
          months                             Nine                               
          ended                              months                             
          Septem…                            ended                              
          30,                                Septe…                             
          (unaud…     2026          2025     30,         2026          2025     
 ────────────────────────────────────────────────────────────────────────────── 
  As                                                                            
  repor…                                                                        
  cost                                                                          
  of               $     3       $     2             $      9       $     8     
  sales                                                                         
  accor…                                                                        
  to                                                                            
  GAAP                                                                          
  Exclu…                                                                        
  compe…                                                                        
  expen…                                                                        
  relat…                 -             -                    -            (1  )  
  to                                                                            
  equity                                                                        
  awards                                                                        
  (1)                                                                           
  Non-G…                                                                        
  cost             $     3       $     2             $      9       $     7     
  of                                                                            
  sales                                                                         
  As                                                                            
  repor…                                                                        
  resea…                                                                        
  devel…                                                                        
  and              $   216       $   218             $    643       $   636     
  patent                                                                        
  expen…                                                                        
  accor…                                                                        
  to                                                                            
  GAAP                                                                          
  Exclu…                                                                        
  compe…                                                                        
  expen…                                                                        
  relat…               (24  )        (21  )               (74  )        (61  )  
  to                                                                            
  equity                                                                        
  awards                                                                        
  Non-G…                                                                        
  resea…                                                                        
  devel…           $   192       $   197             $    569       $   575     
  and                                                                           
  patent                                                                        
  expen…                                                                        
  As                                                                            
  repor…                                                                        
  selli…                                                                        
  gener…                                                                        
  and              $   154       $    97             $    455       $   263     
  admin…                                                                        
  expen…                                                                        
  accor…                                                                        
  to                                                                            
  GAAP                                                                          
  Exclu…                                                                        
  compe…                                                                        
  expen…                                                                        
  relat…               (19  )        (10  )               (58  )        (29  )  
  to                                                                            
  equity                                                                        
  awards                                                                        
  Non-G…                                                                        
  selli…                                                                        
  gener…           $   135       $    87             $    397       $   234     
  and                                                                           
  admin…                                                                        
  expen…                                                                        
  As                                                                            
  repor…                                                                        
  opera…                                                                        
  expen…           $   373       $   317             $  1,107       $   907     
  accor…                                                                        
  to                                                                            
  GAAP                                                                          
  Exclu…                                                                        
  compe…                                                                        
  expen…                                                                        
  relat…               (43  )        (31  )              (132  )        (91  )  
  to                                                                            
  equity                                                                        
  awards                                                                        
  Non-G…                                                                        
  opera…           $   330       $   286             $    975       $   816     
  expen…                                                                        
  As                                                                            
  repor…                                                                        
  loss                                                                          
  from             $  (130  )    $  (160  )          $   (350  )    $  (167  )  
  opera…                                                                        
  accor…                                                                        
  to                                                                            
  GAAP                                                                          
  Exclu…                                                                        
  compe…                                                                        
  expen…                                                                        
  relat…               (43  )        (31  )              (132  )        (91  )  
  to                                                                            
  equity                                                                        
  awards                                                                        
  Non-G…                                                                        
  loss             $   (87  )    $  (129  )          $   (218  )    $   (76  )  
  from                                                                          
  opera…                                                                        
  As                                                                            
  repor…                                                                        
  net                                                                           
  loss             $  (110  )    $  (129  )          $   (317  )    $  (152  )  
  accor…                                                                        
  to                                                                            
  GAAP                                                                          
  Exclu…                                                                        
  compe…                                                                        
  expen…                                                                        
  relat…                                                                        
  to                                                                            
  equity               (43  )        (31  )              (132  )        (91  )  
  awards                                                                        
  and                                                                           
  relat…                                                                        
  tax                                                                           
  effec…                                                                        
  Non-G…                                                                        
  net              $   (67  )    $   (98  )          $   (185  )    $   (61  )  
  loss                                                                          
                                                                                
                                                            
  (1)  Amounts appear as zero due to rounding in millions.  
                                                            
                                       8                                        
                                                                                
  Reconciliation of GAAP to Non-GAAP Basis                                      
                                                                                
As illustrated in the Selected Financial Information in this press release, non-
GAAP operating expenses, non-GAAP loss from operations, and non-GAAP net loss
were adjusted from GAAP to exclude compensation expense related to equity awards
and the related tax effects. Compensation expense related to equity awards are
non-cash. These measures are provided as supplementary information and are not a
substitute for financial measures calculated in accordance with GAAP. Ionis
reports these non-GAAP results to better enable financial statement users to
assess and compare its historical performance and project its future operating
results and cash flows. Further, the presentation of Ionis’ non-GAAP results is
consistent with how Ionis’ management internally evaluates the performance of
its operations.
                                       9                                        
                                                                                
                          IONIS PHARMACEUTICALS, INC.                           
                                                                                
                                                                                
                     Condensed Consolidated Balance Sheets                      
                                                                                
                                 (In Millions)                                  
                                                                                
                             September 30,                 December 31,         
  Assets:                    2026           (unaudited)    2025                 
 ────────────────────────────────────────────────────────────────────────────── 
  Cash, cash equivalents                                                        
  and short-term             $                    1,884    $             2,677  
  investments                                                                   
  Contracts receivable                               88                     66  
  Other current assets                              389                    247  
  Property, plant and                               162                    123  
  equipment, net                                                                
  Right-of-use assets                               228                    239  
  Other assets                                      162                    172  
  Total assets               $                    2,913    $             3,524  
  Liabilities and                                                               
  stockholders’ equity:                                                         
  Current portion of                                                            
  deferred contract          $                       70    $                74  
  revenue                                                                       
  0% convertible senior                                                         
  notes due April                                     -                    432  
  2026, net – current                                                           
  Liability related to                                                          
  sale of future                                    138                     12  
  royalties, net –                                                              
  current                                                                       
  Other current                                     227                    265  
  liabilities                                                                   
  0% convertible senior                                                         
  notes due 2030,                                   754                    751  
  net                                                                           
  1.75% convertible                                                             
  senior notes due 2028,                            570                    568  
  net                                                                           
  Liability related to                                                          
  sale of future                                    428                    551  
  royalties, net                                                                
  Long-term lease                                   262                    262  
  liabilities                                                                   
  Long-term obligations,                                                        
  less current                                       21                     28  
  portion                                                                       
  Long-term deferred                                 49                     92  
  contract revenue                                                              
  Total stockholders’                               394                    489  
  equity                                                                        
  Total liabilities and                                                         
  stockholders’              $                    2,913    $             3,524  
  equity                                                                        
                                                                                
                                       10                                       
                                                                                
  Key 2026 and 2027 Value Driving Events                                        
                                                                                
(1)
                                                                     
  New Product Launches                                               
  Program               Indication         Location      2026  2027  
  DAWNZERA              HAE                EU        Achieved        
  TRYNGOLZA             sHTG               U.S.      Achieved        
  EU                    •                                            
  ZANVASTRO             Alexander disease  U.S.      Achieved        
  HIBSAGO               CHB                Japan     Achieved        
  U.S.                  •                                            
  EU                                       •                         
  China                                    •                         
  Sefaxersen            IgAN               U.S.                   •  
  Ulefnersen            FUS-ALS            U.S.                   •  
                                                                     
                                                                                
  Regulatory                                                                    
  Actions                                                                       
  Program            Indication         Regulatory Action           2026  2027  
  Donidalorsen       HAE                EU approval             Achieved        
                                        decision                                
  Olezarsen          sHTG               U.S. approval           Achieved        
                                        decision                                
  EU submission      Achieved                                                   
  EU approval        •                                                          
  decision                                                                      
  Zilganersen        Alexander disease  U.S. submission         Achieved        
  U.S. approval      Achieved                                                   
  decision                                                                      
  Nusinersen         SMA                EU approval             Achieved        
  (high dose)                           decision                                
  U.S. approval      Achieved                                                   
  decision                                                                      
  Bepirovirsen       CHB                Regulatory              Achieved        
                                        submission(s)                           
  U.S. and Japan                                                                
  approval           Achieved                                                   
  decisions                                                                     
  EU approval                           •                                       
  decision                                                                      
  China approval                        •                                       
  decision                                                                      
  Pelacarsen         Lp(a)- CVD         U.S. submission     Not Achieved        
  Sefaxersen         IgAN               U.S. submission                      •  
  U.S. approval                         •                                       
  Ulefnersen         FUS-ALS            U.S. submission                      •  
  U.S. approval                         •                                       
                                                                                
                                       11                                       
                                                                                
  Key Phase 3                                                                   
  Clinical Events                                                               
  Program            Indication         Event                       2026  2027  
  Obudanersen        Angelman syndrome  REVEAL fully            Achieved        
                                        enrolled                                
  REVEAL data                           •                                       
  Bepirovirsen       CHB                B-Well data             Achieved        
  Pelacarsen         Lp(a)-CVD          Lp(a) HORIZON data  Not Achieved        
  Eplontersen        ATTR-CM            CARDIO-TTRansform   Not Achieved        
                                        data                                    
  Sefaxersen         IgAN               IMAgINATION             Achieved        
                                        interim data                            
  IMAgINATION data                      •                                       
  Ulefnersen         FUS-ALS            FUSION data             Achieved        
  Salanersen         SMA                Phase 3 initiation      Achieved        
  Sapablursen        Polycythemia Vera  Phase 3 initiation      Achieved        
  Diranersen         Alzheimer’s        Phase 3 initiation                   •  
                     disease                                                    
                                                                                
(1)

Tim
ing
exp
ect
ati
ons
bas
ed
on
cur
ren
t a
ssu
mpt
ion
s
and
sub
jec
t
to
cha
nge
.
●

Ind
ica
tes
tha
t
the
mil
est
one
is
ant
ici
pat
ed
in
the
yea
r i
ndi
cat
ed.
                                     # # #                                      
                                                                                
                                       12                                       

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IONS/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.